CSL (ASX:CSL) announced that Dr. Paul McKenzie will retire as CEO and Managing Director, effective immediately.
McKenzie, who led the global biotech leader through post-pandemic supply chain stabilisation and the launch of pioneering gene therapies like HEMGENIX, is stepping down after seven years with the company.
The board has appointed veteran executive and non-executive director Gordon Naylor as interim CEO and Managing Director, effective Feb. 11, while a global search for a permanent successor is conducted.
Naylor brings 33 years of experience at CSL, including previous roles as CFO and President of Seqirus, and will have full authority to lead the company's ongoing strategic transformation.
At the time of reporting, CSL's share price was $171.39.